Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials

CONCLUSIONS: Zoledronic acid is beneficial to reduce the incidence of fracture, while its benefits to reduce the mortality are only observed at the follow-up time of 24 months.PMID:33629326 | DOI:10.26355/eurrev_202102_24865

Source: European Review for Medical and Pharmacological Sciences - February 25, 2021 Category: Drugs & Pharmacology Authors: B He J-Q Zhao M-Z Zhang Z-X Quan Source Type: research